Stockwinners Market Radar for May 02, 2023 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

20:06 EDT Cathie Wood's ARK Investment bought 147K shares of Coinbase today

19:59 EDT Zillow Group builds ChatGPT plugin for real estate searches - Zillow "announced the launch of the Zillow ChatGPT plugin, which gives users a new way to discover real estate listings. Users who enable the plugin can use conversational language to ask about specific property listings or share the types of for-sale and rental homes they are interested in, including location, price range, and bedroom and bathroom count. The Zillow plugin then retrieves relevant information from Zillow's extensive database of real estate listings."

19:12 EDT Rexnord co-CEO Schwimmer sells 35,505 common shares - In a regulatory filing, Rexford Industrial Realty co-CEO Howard Schwimmer disclosed the sale of 35,505 common shares of the company on April 28 at a price of $55.9384 per share.

18:46 EDT Logitech CEO: We love where we are, we're gaining market share - In an interview on CNBC's Mad Money, Bracken Darrell said the company is investing in innovation and received 100 design awards over the past year. "We're in three or four big secular areas. We're poised for growth," he noted.

18:23 EDT Restaurant Brands EC: Food inflation and worker shortages have started to ease - In an interview on CNBC's Mad Money, Patrick Doyle said 40% of the company's earnings come from Tim Hortons and it had an exceptional quarter. It has a strong digital presence in Canada and there is huge upside as only one third of orders come from the app. Driving franchisees at the restaurant level is a priority, he noted.

18:16 EDT Microsoft exec sells $9.18M in common stock - In a regulatory filing, Microsoft disclosed that its Chief Commercial Officer Judson Althoff sold 30K shares of common stock on May 1st in a total transaction size of $9.18M.

18:02 EDT KKR to acquire CoolIT Systems - KKR and CoolIT Systems announced the signing of a definitive agreement under which KKR will acquire CoolIT. The investment will support the Company's ability to scale and serve its global customers across the data center market, including the enterprise, high-performance computing, and cloud service provider segments as well as in desktop computing. Founded in 2001, CoolIT designs, engineers and manufactures advanced liquid cooling solutions for the data center and desktop markets. CoolIT's patented Split-Flow Direct Liquid Cooling technology is designed to improve equipment reliability and lifespan, decrease operating cost, lower energy demand and carbon emissions, reduce water consumption and allow for higher server density than legacy air-cooling methods. As part of this transaction, CoolIT will expand its equity ownership program to make all employees owners of the Company. KKR is investing in CoolIT through its Global Impact strategy. The transaction is expected to close in the Q2, subject to regulatory approvals and customary closing conditions.

17:36 EDT Starbucks says China store traffic rebounded in Q2 - Says Q2 marked "significant turning point" in China. Says doesn't expect straight-line China recovery. Says Japan and U.K. saw double digit SSS growth. Says business and brand "remain strong." Says will continue to face uncertainties for remainder for fiscal 2023.

17:27 EDT Caesars says will generate positive EBITDA in 2023 - Says trends in Las Vegas remained strong in Q1. Says launching new standalone iCasino app in Q3. Says expects to begin testing in-house player count system this year, which is expected to result in shared wallet in 2024. Says expects year-over-year net revenues will continue to grow each quarter. Says still expects capital expenditures of $800M. Says targets third consecutive year of $1B of permanent debt reduction. Says Q2 is generally most difficult comp. Says feels good about business in April and through the rest of the quarter in Vegas. Says weather in Northern Nevada cost about $20M of EBITDA in the quarter. Says will generate positive EBITDA in 2023. Says 80% of digital business is non-Nevada. Says expects digital business EBITDA to breakeven in seven months. Says could be pushing toward $5B of EBITDA by 2025. Comments taken from Q1 earnings conference call.

17:21 EDT Watts Water boosts dividend 20% to 36c per share - Watts Water Technologies declared that the corporation will pay a quarterly dividend of 36c per share on each outstanding share of the company's Class A common ctock and Class B common stock, said dividend to be paid on June 15 to stockholders of record at the close of business on June 1.

17:19 EDT Faraday Future receives additional 180-day extension from Nasdaq - Faraday Future Intelligent Electric announced that the company has received a second 180-day extension to meet NASDAQ's $1 minimum bid price requirement for ten consecutive trading days from NASDAQ Stock Market LLC. With this extension, the company has been given an additional 180 days to regain compliance.

17:13 EDT IN8bio to present data on potential of INB-400 to target ovarian cancer - IN8bio will present preclinical data showcasing the potential of INB-400 to target ovarian cancer at the American Society of Cell & Gene Therapy, ASGCT, Annual Meeting, in Los Angeles from May 16-20. High-grade serous ovarian cancer, HGSOC, is the most common and devasting form of ovarian cancer, comprising approximately 70-80% of deaths. While poly ADP-ribose polymerase inhibitors, PARPi, have improved patient outcomes, recurrence remains a significant obstacle and unmet medical need. INB-400 is an O6-methylguanine-DNA methyltransferase genetically engineered, chemotherapy resistant gamma-delta T cell product that can recognize and kill cancer cells. INB-400 has shown promising results in preclinical studies, demonstrating a powerful synergistic combination of chemotherapy and gamma-delta T cell therapy to eliminate residual cancer cells. The new data to be presented at ASGCT builds on that success, demonstrating the ability of INB-400 to target and kill multiple ovarian cancer cell lines. "We believe the technology targeting the DNA damage response pathway underlying our INB-400 program has broad applicability across many solid tumor cancers," said Lawrence Lamb, Ph.D., co-founder and Chief Scientific Officer of IN8bio. "These data demonstrate the potential of gamma-delta T cells to target and kill solid tumor cells outside the brain. We are encouraged by these findings and will continue exploring the potential of INB-400 across a broad range of solid tumors where new treatment options are urgently needed."

17:00 EDT Delek US raises quarterly dividend to 23c from 22c per share - The dividend will be paid on May 22, 2023, to shareholders of record on May 15, 2023.

16:50 EDT Box unveils Box AI, to integrate advanced AI models with Box Content Cloud - Box unveiled Box AI, a new suite of capabilities that will natively integrate advanced AI models into the Box Content Cloud, bringing Box's enterprise-grade standards for security, compliance, and privacy to this breakthrough technology. Box AI will make it easier than ever to uncover and share insights, find timely answers to critical questions, and effortlessly create content based on an organization's data in Box. The company also announced that it will integrate OpenAI's most advanced AI models with the Box Content Cloud, further enabling new ways to understand and create content on Box. "We are at the start of a platform shift in enterprise software driven by recent advancements in generative AI, and nowhere is the potential impact greater than in enterprise content," said Aaron Levie, Co-Founder and CEO of Box. "We've seen a step function improvement in our ability to analyze and synthesize the massive amounts of data contained within an organization's unique documents, videos, presentations, spreadsheets, and more. When combined with AI, we will be able to unlock the value of this content and make every person in a company smarter and more productive. Content is an organization's most important data, and with Box AI we're just getting started with how we'll transform the way work gets done."

16:45 EDT NerdWallet falls 9% to $11.43 after Q1 earnings

16:42 EDT Herbalife falls 9% to $12.97 after Q1 earnings miss

16:40 EDT Viracta Therapeutics CMO Lisa Rojkjaer, M.D to depart - Viracta Therapeutics announced that Chief Medical Officer, Lisa Rojkjaer, M.D., will be leaving the company to pursue another opportunity, effective May 5, 2023. Donald Strickland, M.D., Viracta's Vice President, Clinical Development and Medical Director, and Yisrael Katz, M.D., Senior Medical Director, will continue to oversee Viracta's pivotal NAVAL-1 trial and solid tumor clinical program, respectively.

16:38 EDT Galapagos announces departure of COO and CFO Bart Filius - Galapago announced the departure of Bart Filius, President, Chief Operating Officer and Chief Financial Officer. Bart Filius joined Galapagos in 2014 as Chief Financial Officer and subsequently took on the responsibility as Chief Operating Officer in 2017. In 2021, he was named President of the company. In his roles, Bart oversaw finance, business development, commercial strategy, human resources, and other business operations.

16:37 EDT Aurinia says ISS recommends holders vote for company's board nominees - Aurinia Pharmaceuticals Inc. announced that leading independent proxy advisor Institutional Shareholder Services has recommended that Aurinia shareholders vote FOR the re-election of all eight incumbent directors to the Board of Directors at the Company's 2023 Annual General Meeting. ISS' positive recommendation follows an April 26 report from Glass Lewis, another leading independent proxy advisor, which also recommended that shareholders vote for the re-election of all incumbent directors. "Aurinia is pleased that ISS and Glass Lewis recognize the Board and management's pivotal role in the Company's continued growth and momentum," the company said. "Aurinia's Board also appreciates the feedback and continued strong support of our shareholders."

16:34 EDT Esquire Financial raises quarterly dividend 25% to 12.5c per share - Payable on June 1 to each stockholder of record on May 15.

16:32 EDT Yum China 2023 targets remain unchanged - The company's fiscal year 2023 targets remain unchanged: To open approximately 1,100 to 1,300 net new stores. To make capital expenditures in the range of approximately $700M-$900M.

16:32 EDT Murphy USA announces new $1.5B share repurchase program - The Board of Directors of Murphy USA Inc. recently authorized a new share repurchase authorization of up to $1.5B to begin upon completion of the current $1B authorization and to be executed by December 31, 2028. The new authorization reaffirms the company's commitment to supplement organic growth initiatives with shareholder distributions, including its dividend growth plan, to maximize value creation over time. "Shareholder value creation is at the forefront of Murphy USA's strategy, and as part of that strategy we remain deeply committed to returning capital to shareholders," said President and CEO Andrew Clyde. "We are increasingly confident in the future of Murphy USA given our exceptional operating performance, accelerating organic growth profile and ongoing business improvement initiatives. This timeframe provides management added flexibility over a 5-year window to fully fund a growing store pipeline and allocate increasing free cash flow to the highest and best return investments, prioritizing share repurchase given our view of the future potential of Murphy USA."

16:31 EDT Assurant sees FY23 adj. EBITDA, ex. reportable catastrophes, up low single-digit - Assurant said the company continues to expect adjusted EBITDA, excluding reportable catastrophes, to increase low single-digits, driven by improved performance in Global Housing and more modest growth in Global Lifestyle, and adjusted earnings, excluding reportable catastrophes, per diluted share, growth rate to be lower than Adjusted EBITDA growth due to increased depreciation expense and a higher effective tax rate.

16:28 EDT Clearwater expects paperboard demand to improve in second half - The company said, "We expect demand for paperboard to improve in the second half versus the first half as we believe that customers will adjust their inventories and end users will return to more normal buying patterns. We will continue to monitor our paperboard inventories and intend to match supply with demand as needed. We expect continued strength in our tissue business in the coming quarters, with anticipated strong demand and moderating input costs driving margin improvement."

16:26 EDT Paycom initiates 37.5c per share quarterly dividend - The Company intends to pay dividends at an annual rate of $1.50, payable quarterly in the amount of $0.375 per share, with the inaugural quarterly dividend anticipated to be paid in mid-June, subject to Board approval.

16:22 EDT Herbalife announces retirement of Mark Schissel, names Frank Lamberti COO - Herbalife announced senior executive leadership changes. As part of its succession management process, the company is announcing Mark Schissel's retirement on July 1. Frank Lamberti will be appointed to Chief Operating Officer. In addition, the company is announcing the expanded role of Ibi Montesino, EVP and Chief of Staff, and the appointment of Rob Levy to Regional President of the Americas. All three executives will assume their roles effective July 1. Schissel will assume a strategic advisory role to help ensure a smooth transition and will continue to work on special projects.

16:22 EDT WestRock to close paper mill in North Charleston - WestRock Company announced it will permanently cease operating its paper mill in North Charleston, South Carolina, on August 31, 2023. "WestRock and its predecessor companies have had a long history in the region operating the North Charleston mill, and the contributions of the team members over the years have been greatly appreciated," said David B. Sewell, chief executive officer at WestRock. "The decision to close a facility and impact the lives of our team members is never easy, and we are committed to assisting our North Charleston team with exploring roles at other WestRock locations and outplacement assistance." The North Charleston mill employs approximately 500 people. Employees will receive severance and outplacement assistance in accordance with WestRock policy and labor union agreements.

16:19 EDT Match 'remains confident' revenue can exit FY23 with double digit y/y growth - The company said, "As we start to see the benefits of the work at Tinder, we remain confident that the Company's Total Revenue and Tinder Direct Revenue can both exit 2023 with double digit Y/Y growth. The lower than initially expected first half of 2023 business performance may contribute to full year Match Group Total Revenue and Tinder Direct Revenue growth rates closer to the low end of our previously communicated ranges of 5% to 10% Y/Y. That said, we've already seen improved momentum in April and there are numerous initiatives in flight that could drive incremental growth this year, so we are eager to see how those progress. Note that we estimate $17 million more of Y/Y FX headwinds for Q2 to Q4 than we anticipated at the time of our last earnings call."

16:17 EDT Simon Property raises quarterly common stock dividend 15c to $1.85 per share - Simon's board of directors declared a quarterly common stock dividend of $1.85 for the second quarter of 2023. This is an increase of 15c, or 8.8% year-over-year. The dividend will be payable on June 30 to shareholders of record on June 9.

16:13 EDT Clorox reports Q3 gross margin up 590 bps to 41.8% from 35.9% a year ago

16:10 EDT Starbucks to discuss FY23 financial targets during call - "The company will discuss fiscal year 2023 financial targets during its Q2 FY23 earnings conference call starting today at 2:00 p.m. Pacific Time. These items can be accessed on the company's Investor Relations website during and after the call," Starbucks stated.

16:08 EDT Starbucks CEO 'very pleased' with Reinvention progress - "I am very pleased with our Reinvention progress and grateful for the opportunity to fully immerse into the company, which I formally took over on March 20, 2023. It is a privilege to have learned from our founder and partners around the world. From my immersion observations, our leadership team now has a clear line of sight into our growth headroom, as well as our opportunities to enhance margins and modernize the business, brand, partner experience and culture of Starbucks. As we strive to continue to be a different kind of company, we will unlock our limitless possibilities to meet the needs of today and, importantly, the future of Starbucks," commented CEO Laxman Narasimhan.

16:07 EDT Starbucks reports U.S. Rewards membership up 15% to 30.8M members - Starbucks Rewards loyalty program 90-day active members in the U.S. increased to 30.8 million, up 15% year-over-year, the company announced.

16:04 EDT Moving iMage, SNDBX expand strategic partnership - Moving iMage Technologies and SNDBX, a division of The Five Agency, LLC and an emerging developer and operator of amateur Esports leagues played locally on the big screen, announced an expansion to their strategic partnership to accelerate the growth of local amateur Esports leagues. "Our enhanced partnership with SNDBX brings two leading, entrepreneurial companies closer together to capture this significant market opportunity," said Joe Delgado, executive vice president, sales and marketing. "This agreement formalizes our partnership and incentivizes both companies to work in tandem to grow the market for SNDBX's Esports offerings in the U.S. and on a global scale."

16:01 EDT Caesars reports Q1 adjusted EBITDA $958M vs. $296M last year

14:56 EDT Coinbase launches International Exchange amid Bermuda licensing approval - Coinbase said, in part, earlier in a blog post: "At Coinbase, we're working hard to help update the financial system by building trusted products that expand the utility and adoption of crypto because we believe crypto and blockchain technology have the ability to increase economic freedom and opportunity around the world...Coinbase is dedicated to partnering with high-bar regulators across US and non-US jurisdictions to help update the financial system by developing additional solutions and products, leveraging our high standards of customer protection and robust risk management frameworks. With the recent approval of our regulatory license from the Bermuda Monetary Authority, BMA, today we are excited to announce the launch of Coinbase International Exchange...Coinbase International Exchange will enable institutional users based in eligible jurisdictions outside of the US, to trade perpetual futures. Perpetual futures accounted for nearly 75% of global crypto trading volume in 2022, creating highly-liquid markets and offering traders additional versatility in their trading strategies." Reference Link

14:32 EDT Paccar, Toyota expand hydrogen fuel cell truck collaboration - Paccar (PCAR) and Toyota Motor North America (TM) announced an expansion of their joint efforts to develop and produce zero emissions, hydrogen fuel cell Kenworth and Peterbilt trucks powered by Toyota's next-generation hydrogen fuel cell modules. "The expanded agreement supports ongoing development and commercialized zero-emission versions of the Kenworth T680 and Peterbilt 579 models featuring Toyota's hydrogen fuel cell powertrain kit, with initial customer deliveries planned for 2024... Toyota will begin assembly of the modules in the United States in late 2023," the companies stated.

13:49 EDT Subaru reports April U.S. sales up 11.5% to 51,014 vehicles - Subaru of America reported 51,014 vehicle sales for April, an 11.5% increase compared with April 2022 sales of 45,748 units.

13:15 EDT Amazon launches new fulfillment center in Windsor, Connecticut - Amazon, along with Gov. Ned Lamont, Lt. Gov. Susan Bysiewicz, state and local elected officials, and community partners, celebrated the official opening of its new, state-of-the-art fulfillment center in Windsor, Connecticut. More than 2,000 local Amazon employees will operate and work with the newest innovative robotics technology, delivering for customers in the area. This new facility expands Amazon's robust operations and logistics network in the state, where there are more than 15,000 full and part-time employees across Connecticut communities. "I am thrilled Amazon is investing further into the great state of Connecticut with the opening of its new fulfillment center in Windsor," said Governor Ned Lamont. "This fulfillment center is adding more than 2,000 well-paid jobs with excellent benefits into the Greater Hartford economy, and I look forward to the impact it will have on the region and state for years to come."

12:07 EDT 3M to sell dental local anesthetic portfolio assets to Pierrel for $70M - 3M announced it has entered into agreements to sell certain assets associated with its dental local anesthetic portfolio, based in Seefeld, Germany, to Pierrel S.p.A., a global provider of services for the pharmaceutical industry, for a purchase price of $70M, subject to closing and other adjustments. 3M's local anesthetic products, sold primarily in Europe and Asia, include products sold under the Ubistesin, Xylestesin and Mepivastesin brands together with related syringe and needle products and are part of the dental materials business in 3M's Oral Care Solutions Division. As part of ongoing strategic portfolio management, 3M has decided to exit these products and prioritize investments that leverage its Health Care business' core Oral Care technologies. "We believe that these products will be well positioned with Pierrel," said Karim Mansour, president, 3M Oral Care Solutions Division. "3M will continue to invest in oral care solutions for our Europe and Asia customers and those around the world." These local anesthetic products had annual sales in 2022 of approximately $30M and the impact of ongoing operations were not material to 3M's financial results. The transaction, which is subject to information or consultation requirements with relevant works councils and other closing conditions, is expected to be completed in the third quarter of 2023. 3M expects to record a gain upon this business's divestiture which it will reflect as an adjustment in arriving at results, adjusted for special items. After the transaction closes, 3M will provide transition support to Pierrel to help facilitate a smooth transition for customers. 3M will retain ownership of its Seefeld facility and operations, which support 3M's Oral Care business.

12:01 EDT E2open falls -26.4% - E2open is down -26.4%, or -$1.65 to $4.59.

12:01 EDT Chegg falls -48.3% - Chegg is down -48.3%, or -$8.51 to $9.10.

12:01 EDT Natuzzi rises 9.6% - Natuzzi is up 9.6%, or 48c to $5.48.

12:00 EDT Leju rises 53.5% - Leju is up 53.5%, or $1.90 to $5.46.

11:52 EDT Harmony Gold announces loss of life incident at Kusasalethu Mine - Harmony Gold Mining Company Limited announced in a regulatory filing a loss of life incident at its Kusasalethu Mine, near Carletonville on Sunday, 30 April 2023. A seismic induced fall of ground event resulted in the loss of life of one of its night shift team leaders. The management and employees of Harmony express their sincerest condolences to the family of the deceased and to the Kusasalethu team who have been affected by this tragic incident. Peter Steenkamp, the Chief Executive Officer, stated, "I am deeply disappointed by this loss of life, especially considering the significant efforts we have made to foster a safety culture within our organisation." Safety is at the core of Harmony's values, and the company continues to prioritise rigorous safety standards throughout all of its operations, the company said. All work in the affected section has been temporarily ceased, pending a comprehensive internal investigation.

10:48 EDT Thoughtworks up 20% after Bloomberg report on possible buyout bid - Shares of Thoughtworks are up $1.28, or 20%, to $7.50 following Bloomberg's report.

10:43 EDT Lilium up 20% after announcing capital raise - Lilium, which identifies itself as the "developer of the first all-electric vertical take-off and landing jet,: announced a capital raise for up to $250M, with $100M funded at close. "This capital raise enables Lilium to continue the development of its Lilium Jet at full pace and would cover most of the estimated capital required to achieve first manned flight of the type-conforming aircraft. Once this development milestone is achieved, which is planned for the second half of 2024, Lilium expects to benefit from the contribution of substantial pre-delivery payments which will help fund its subsequent capital requirements," the company stated. Lilium CEO Klaus Roewe added, "The capital raise announced today marks an important development in our ongoing mission to revolutionize the aviation industry. With this financing, we are excited to continue our development program at full pace. We remain in multiple constructive discussions with existing and potential new investors. We hope to announce further updates soon." Shares of Lilium are up 8c, or 20%, to 46c in early trading.

10:37 EDT Thoughtworks trading halted, volatility trading pause

10:32 EDT Apple, Google lead initiative for specification to address unwanted tracking - Apple (AAPL) and Google (GOOGL) jointly submitted a proposed industry specification to help combat the misuse of Bluetooth location-tracking devices for unwanted tracking. "The first-of-its-kind specification will allow Bluetooth location-tracking devices to be compatible with unauthorized tracking detection and alerts across iOS and Android platforms. Samsung, Tile, Chipolo, eufy Security, and Pebblebee have expressed support for the draft specification, which offers best practices and instructions for manufacturers, should they choose to build these capabilities into their products," Apple and Google said. The specification has been submitted as an Internet-Draft via the Internet Engineering Task Force, a standards development organization. Interested parties are invited and encouraged to review and comment over the next three months. Following the comment period, Apple and Google will partner to address feedback, and will release a production implementation of the specification for unwanted tracking alerts by the end of 2023 that will then be supported in future versions of iOS and Android. Reference Link

10:23 EDT AnPac Bio Medical Science Company trading halted, volatility trading pause

10:19 EDT Western Alliance trading resumes

10:17 EDT Jupiter Wellness Acquisition Corp trading halted, volatility trading pause

10:14 EDT Western Alliance trading halted, volatility trading pause

10:13 EDT Ford re-opens orders for Mustang Mach-E with higher EPA est. range - Ford announced that it is re-opening its order banks for the all-electric Mustang Mach-E on Wednesday as completed plant upgrades support production ramp in the second half of 2023, with feature improvements on the way - including increased range for standard range battery models to an EPA-estimated targeted range of 250 miles for RWD and 226 miles for eAWD. The production increase for Mustang Mach-E in the second half of this year is part of Ford's plan to scale electric vehicles and make them more accessible and affordable for customers, the company said in a statement. "We continue to find ways to improve the value of the Mustang Mach-E," said Marin Gjaja, chief customer officer, Ford Model e. "Upgraded BlueCruise rolling out for new and existing Mustang Mach-E owners, increased range and faster DC charging times on standard range models show how we are relentlessly improving our products for our customers."

10:08 EDT PacWest Bancorp trading resumes

10:04 EDT Sysco continuing to target net debt to adjusted EBITDA ratio of 2.50-2.75x - Comments taken from Q3 earnings conference call.

10:01 EDT L3Harris Technologies to develop U.S. Air Force Common Tactical Edge Network - L3Harris Technologies received a U.S. Air Force contract award to develop a Common Tactical Edge Network providing an aerial military Internet of Things to support the Advanced Battle Management System and Joint All-Domain Command and Control initiatives. The system will include a meshed network of defense and commercial resources, enhancing aerial interoperability for U.S. and allied forces by incorporating commercial-like, high-speed data processing and sharing at the tactical edge. CTEN will initially connect Air Force aerial platforms that currently operate with incongruent network architectures with the potential to improve connectivity across the entire joint force. CTEN's data fusion will enable warfighters controlling multiple platforms to think and operate as one, greatly shortening the decision cycle.

10:00 EDT Community Health falls -41.5% - Community Health is down -41.5%, or -$2.58 to $3.65.

10:00 EDT Ameresco rises 10.3% - Ameresco is up 10.3%, or $4.22 to $45.00.

10:00 EDT Leju rises 110.4% - Leju is up 110.4%, or $3.93 to $7.49.

09:52 EDT WisdomTree urges shareholders to vote for director nominees - WisdomTree issued a letter to its stockholders urging them to vote for WisdomTree's director nominees at WisdomTree's 2023 Annual Meeting of Stockholders, which is scheduled to be held on June 16, 2023. The letter says, in part: "A dissident stockholder, ETFS Capital Limited, seeks to elect three representatives, including its chairman, Graham Tuckwell, to the WisdomTree Board of Directors. We believe that Mr. Tuckwell's continued crusade against WisdomTree is driven purely by his personal agenda and ego, rather than by any consideration of what is best for the Company and its stockholders. We urge you NOT to sign or return any proxy card or voting instruction form that may be sent to you by ETFS Capital, and to "WITHHOLD" your vote from all three ETFS Capital nominees."

09:49 EDT Terreno Realty sells industrial property in New Jersey for $25.5M - Terreno Realty sold an industrial property located in North Bergen, New Jersey on May 1 for a sale price of approximately $25.5M. The property consists of one industrial distribution building containing approximately 127,000 square feet on 4.4 acres which is 100% leased to one tenant. The property was purchased by Terreno Realty on April 20, 2017 for approximately $14M. The unleveraged internal rate of return generated by the investment was 14.4%.

09:47 EDT Community Health falls -38.5% - Community Health is down -38.5%, or -$2.40 to $3.83.

09:47 EDT Flowserve rises 9.8% - Flowserve is up 9.8%, or $3.33 to $37.25.

09:47 EDT Leju rises 61.2% - Leju is up 61.2%, or $2.18 to $5.74.

09:42 EDT JX Luxventure Ltd trading resumes

09:37 EDT JX Luxventure Ltd trading halted, volatility trading pause

09:35 EDT GD Culture Group Ltd trading resumes

09:32 EDT Deluxe, ECHO Health to form JV, DPX Payments - Deluxe and ECHO Health have joined forces to create DPX Payments, a joint venture to deliver advanced payables offerings to the large and underserved middle-market. The new venture will offer a comprehensive disbursements platform specifically designed for businesses that send thousands of routine or recurring payments to suppliers and vendors using paper today. With multiple digital payment types from which to choose and enhanced security, this solution offers seamless integration with the most popular accounting software platforms, reducing manual processes and mitigating the risk of fraud for small- and mid-sized businesses. Deluxe and Echo first partnered in 2019 with the launch of the Medical Payment Exchange, which, along with the existing Deluxe Payment Exchange, is growing rapidly, processing more than $20B in payments annually. The new JV expands the partnership to offer these advanced payment capabilities to all businesses, with support for multiple payment types, including ACH, virtual card, paper check, push to debit card, and echeck, among others. The joint venture will leverage the extensive network of businesses with existing relationships with Deluxe enabling significant scale over time.

09:31 EDT E2open Parent Holdings trading halted, volatility trading pause

09:24 EDT Irwin Naturals says BC Securities Commission issues failure-to-file CTO - Irwin Naturals announces that the British Columbia Securities Commission has issued a failure-to-file-cease trade order pursuant to National Policy 11-207 - Failure to File Cease Trade Orders and Revocations in Multiple Jurisdictions in respect of the securities of the Company as a result of the Company not having filed its annual financial statements and management's discussion and analysis and related officer certifications for the financial year ended December 31, 2022 which were required to be filed by May 1, 2023. The CTO prohibits the trading, whether direct or indirect, by any person of any securities of the Company in each jurisdiction in Canada in which the Company is a reporting issuer for as long as the CTO remains in effect, subject to certain limited exceptions. The delay in filing the Required Filings is a result of additional time required by the auditor to review several acquisitions completed by the Company during the 2022 fiscal year. The Company has also entered into multiple definitive agreements during the 2022 fiscal year, which has required considerable time and resources from the finance department of the Company and the auditor. For further details related to these events, please refer to the Company's press releases and the Company's interim financial statements for the period ended September 30, 2022 and the accompanying Management's Discussion and Analysis. The Company is continuing to work with the auditor to complete the Required Filings as soon as possible, at which point the Company will seek to have the CTO revoked. However, there is no assurance that the Company will be able to remedy its filing default and have the CTO revoked in a timely manner or at all.

09:21 EDT AnaptysBio announces publication of data from Phase 2 GALLOP study - AnaptysBio announced the publication of data from the open-label, single-arm Phase 2 GALLOP study evaluating the efficacy, tolerability and safety of imsidolimab, its investigational anti-interleukin-36 receptor IgG4 antibody for the treatment of generalized pustular psoriasis, in the British Journal of Dermatology. Patients with GPP who received a single dose of imsidolimab demonstrated a rapid and sustained improvement of symptoms and pustular eruptions of GPP flare within days after initiating treatment. "We remain excited and quite pleased with the dramatic effects demonstrated by imsidolimab's Phase 2 efficacy and safety data and the potential benefit to patients suffering with life threatening inflammatory GPP," said Paul F. Lizzul, chief medical officer of AnaptysBio. "We look forward to sharing the top-line data on the efficacy, safety and tolerability of a single dose IV infusion of imsidolimab in moderate-to-severe GPP patients from the ongoing GEMINI-1 Phase 3 trial in Q4 2023, whereafter we plan to out license the program prior to a potential FDA approval." In the Phase 2 GALLOP study, a total of eight adult patients with GPP flare were enrolled and received a 750mg IV dose of imsidolimab and six patients were evaluable at both Day 29 and Day 113 and who also completed the study. Clinical responses were observed as early as Day 3, most rapidly for pustulation relative to other visible manifestations of GPP, with continued and consistent improvement across multiple efficacy assessments at Day 8, Day 29, and through Day 113. Of the six patients evaluable on Day 29, all achieved the primary endpoint of clinical response on the clinical global impression scale. Additionally, the GPP Physician Global Assessment scale was implemented by protocol amendment during the trial and was assessed in four of the eight enrolled patients, where zero or one response was achieved in 50% patients at Week 4. Six of eight patients received a monthly 100mg subcutaneous dose of imsidolimab beginning at Week 4 and continued through Week 12. At Week 16, 75% of evaluable patients were responders on the GPPPGA scale. Imsidolimab was generally well-tolerated. Most treatment-emergent adverse events were mild to moderate in severity. Initial top-line Phase 2 study results were presented at European Academy of Dermatology and Venerology Congress in October 2021.

09:15 EDT Volcon aligns with EV charging solutions providers InCharge, Qmerit - Volcon announced that it will expand its dedication of purposeful relationships by collaborating with two EV charging solutions providers, InCharge Energy and Qmerit. Each charging solutions provider will offer respective audiences with tailored charging solutions, giving both consumers and dealers options for charging their electric Volcon vehicles. The agreements come at a time when many OEMs are including EVs in their product roadmaps or have goals to pivot entire fleets to electric all together. "Buying an EV is only the beginning, and it's important to us that we guide our customer through their EV journey after the point of purchase," says Volcon CEO, Jordan Davis. "Once you invest in an EV, you need an accessible and easy solution for charging it. We want to provide our customers with those solutions along the way. It's also about developing relationships with companies who share a similar vision and working with them in unison to help propel this technology to the masses." Davis added.

09:12 EDT Vir receives new $10M grant from the Bill & Melinda Gates Foundation - Vir Biotechnology announced that it received a new $10M grant from the Bill & Melinda Gates Foundation to support Vir's novel T cell vaccine development program. The new grant will support the Phase 1 clinical development of VIR-1388, an investigational novel T cell vaccine for the prevention of human immunodeficiency virus. Using applied learnings from VIR-1111, Vir's initial investigational proof-of-concept HIV T cell vaccine, VIR-1388 is designed to elicit T cells that recognize different HIV epitopes with the goal of creating a safe and effective HIV vaccine. Through close scientific partnership with the National Institute of Allergy and Infectious Diseases and the HIV Vaccine Trials Network, the Phase 1 trial of VIR-1388 is expected to begin in the second half of 2023. The trial will also be funded in part by NIAID, part of the National Institutes of Health, through grant funding to HVTN. NIAID has provided funding throughout the product development lifecycle of VIR-1388. "Vir's long-standing support from the Bill & Melinda Gates Foundation has been a formative part of our company history in global health," said Rajesh Gupta, M.D., M.S., M.P.H., Vice President, Global Health Portfolio and Public-Private Partnerships at Vir Biotechnology. "This new grant underscores the importance of our goal of developing innovative solutions for the prevention and treatment of global infectious diseases, including HIV. We look forward to advancing VIR-1388 into the clinic later this year."

09:11 EDT OSI Systems receives $12M order - OSI Systems announced that its Healthcare division, Spacelabs Healthcare, received an order valued at approximately $12M to provide patient monitoring solutions to a U.S. based hospital, highlighting Spacelabs' ability to provide advanced network security and industry-leading clinical workflow solutions.

09:10 EDT Franklin Resources acquires managed option firm volScout, no terms - Franklin Resources announced that it has acquired volScout, an early-stage business delivering managed options strategies to advisors serving wealth management and institutional clients, and has hired its founding partners, Brad Berggren, Jon Orseck and Roger Weber. With this transaction, Franklin Templeton, a leading separately managed account provider with approximately $110B in SMA assets under management, adds managed options strategies to its comprehensive suite of custom solutions capabilities. volScout founding partners Berggren, Orseck and Weber have decades of industry experience developing market-leading technology platforms used to manage derivative-based SMAs and funds and have held a number of senior roles in derivatives throughout their long careers.

09:08 EDT ESS Inc: Company has 62 patents for innovative energy storage technology - ESS Tech, has been awarded over 20 additional patents for the company's industry-leading iron flow battery IFB technology since the beginning of 2022. This brings the total number of patents held by the company to 62 worldwide with a further 225 applications filed. Founded in 2011, ESS has built an extensive portfolio of patents, proprietary knowledge, and experience in scaling the commercial manufacturing and deployment of iron flow battery systems. ESS' innovations have addressed the critical advancements needed to facilitate mass adoption of IFB technology including the company's patented Electrolyte Health Management System . Collectively, these innovations have created systems capable of delivering unlimited cycling with zero capacity-fade over their operating life. "Solving the world's big energy challenges requires research and innovation," said Julia Song, CTO of ESS. "We are proud of our team's work to develop long-duration energy storage solutions and are grateful for the validation of our distinct innovations by U.S. and global officials. We look forward to the continued advancement of our technology and the competitive advantage it creates in the marketplace as we enable the rapid expansion of wind and solar generation and catalyze the clean energy future."

09:07 EDT Marriott plans to launch new extended stay brand for U.S., says CEO

09:07 EDT Lucid: SEC concludes investigation, does not intend to recommend action - In a regulatory filing, Lucid Group notes that it previously received a subpoena from the SEC requesting the production of certain documents in an investigation by the SEC related to the business combination between the company and Atieva, Inc. and certain projections and statements. The company responded and fully cooperated with the SEC in its review. Lucid added: "On April 27, 2023, SEC staff informed the company that they have concluded the investigation and that they do not intend to recommend an enforcement action by the SEC against the company."

09:06 EDT WalkMe announces availability of WalkMe Discovery - WalkMe announced the availability of WalkMe Discovery, the latest innovation in the evolution of digital adoption technology. WalkMe Discovery gives IT executives and enterprise software owners unprecedented visibility into their enterprise software stack. WalkMe Discovery automatically detects all the web-based apps a company is running, who is using what software, and whether they're using it as intended. Paired with WalkMe's unmatched capabilities to drive software adoption, companies now have a broader range of choices to maximize ROI once they understand the real inefficiencies in their software stack. "Optimizing software spend and driving efficiencies isn't just about reducing costs, it's about driving adoption of technology to ensure enterprises are not only paying for what they need, but also getting what they paid for," said Dan Adika, CEO & Co-Founder, WalkMe. "With the availability of WalkMe Discovery, WalkMe is the only provider that helps enterprises maximize the efficiency of software spend with insight into opportunities for enterprise-wide cost savings and with solutions for improving adoption, unlike point solutions that only provide one or the other."

09:05 EDT First Republic trading halted, news dissemination

09:04 EDT DoubleVerify down 7% in pre-market trading following Spruce Point short call

09:03 EDT TaskUs launches first Technology and Innovation Center in Chennai, India - TaskUs launched its first Technology and Innovation Center. Located in Chennai, India, the Center houses developers building next generation technologies such as Generative AI and Machine Learning products for TaskUs clients and operations around the world. "TaskUs' vision is to become the world's largest tech-enabled business service provider, helping clients solve their most complex problems," said Chandra Venkataramani, Chief Information Officer at TaskUs. "Our new hub is a place for the brightest technologists to collaborate and create together. The Chennai facility is a central gathering spot for our developers to work on and deliver technologies that will increase TaskUs' efficiency and aid our clients as they seek to automate processes and maximize next-gen technologies such as Generative AI."

09:02 EDT Spruce Point issues "Strong Sell" on DoubleVerify

09:00 EDT Elanco provided USDA license for Canine Parvovirus Monoclonal Antibody - Elanco announced the U.S. Department of Agriculture, or USDA, has provided a conditional license for the first Canine Parvovirus Monoclonal Antibody. This is the first and only approved therapeutic solution proven to treat canine parvovirus, one of the most contagious and deadly viruses a dog can contract with a 91% mortality rate if not treated with supportive care. The treatment is the first monoclonal antibody for Elanco.

08:54 EDT NLS Pharmaceutics receives FDA approval to proceed with Phase 3 AMAZE program - NLS Pharmaceutics announced that the U.S. Food and Drug Administration provided authorization to proceed with the Phase 3 program for Quilience. The AMAZE Program will encompass two double-blind Phase 3 trials investigating Mazindol ER versus placebo in adult patients with narcolepsy, commencing this summer at multiple sites in the U.S. Both phase 3 trials, NLS-1031 and NLS-1032, will measure the weekly cataplexy episodes as the primary endpoint over 8 weeks of treatment. Patients who complete these studies will be offered participation in a 12-month open-label extension study. To be eligible for enrollment into the program, patients must be at least 18 years of age and have been diagnosed with narcolepsy with cataplexy. NLS previously reported on the Phase 2 study results in narcolepsy in which Quilience met all primary and secondary endpoints. Patients treated with Mazindol ER in the randomized Phase 2 trial showed continued improvement after rolling over into the OLE study and patients treated with placebo in the randomized Phase 2 trial and who subsequently received Mazindol ER in the OLE study achieved comparable results to the Mazindol ER-treated patients in the Phase 2 trial. Data from the Phase 2 studies will be presented at SLEEP 2023, the annual meeting of the American Academy of Sleep Medicine and the Sleep Research Society, which is being held from June 3 - 7, 2023, in Indianapolis.

08:51 EDT Arteris IP says Tenstorrent licenses Ncore, FlexNoC interconnect IP - Arteris announced Tenstorrent has licensed Ncore and FlexNoC interconnect IP for its AI chiplet systems. The flexible network-on-chip interconnect meets the demanding time-to-market and performance requirements needed to deliver the future generation of AI solutions for edge devices, edge servers and cloud servers.

08:48 EDT Loop Industries, SK Geo Centric sign JV agreement - Loop Industries and SK Geo Centric announced they have signed a definitive Joint Venture Agreement to deploy Loop's technology in the Asian market through multiple commercial manufacturing facilities. SKGC will own 51% of the venture, which will be headquartered in Singapore, and Loop will have the remaining 49% ownership. Under the JVA, the venture will have exclusive rights to commercialize Loop's technology in the Asian market for a prescribed period and Loop will license its technology for an annual royalty for each of the commercial plants. The first planned commercial manufacturing facility with Infinite Loop technology, located in Ulsan, South Korea, will have an annual capacity to supply 70,000 metric tons per year of Loop PET resin for packaging and polyester fiber applications, and is anticipated to break ground in 2023 and to have construction completed by the end of 2025. In addition to Infinite Loop Ulsan, the two partners have outlined plans which target a minimum of three additional commercial manufacturing facilities to be constructed throughout Asia by 2030. Loop and SKGC have partnered with SK ecoengineering, a subsidiary of the SK Group that brings a wealth of expertise as an EPC contractor, for the engineering and construction of the commercial manufacturing facilities.

08:46 EDT XS Financial provides $7.5M capex lease facility to Northeast Alternatives - XS Financial entered into a new lease agreement with Northeast Alternatives, a vertically integrated Massachusetts and Michigan operator. NEA has been approved for a $7.5M CAPEX lease facility, with an immediate drawdown of over $1M, to purchase equipment with up to 60-month terms. This equipment acquisition will enhance the capabilities of existing processing facilities and buildouts for their operations.

08:45 EDT Mynaric receives order for CONDOR terminals from Loft Federal - Mynaric entered into a definitive agreement for the sale of CONDOR Mk3 terminals to Loft Federal, a subsidiary of Loft Orbital. Loft Federal was selected to produce, deploy and operate NExT - the Space Development Agency's Experimental Testbed and will use the terminals to support secure and reliable communications. Terminal deliveries are primarily scheduled for the first half of 2024. The order announced today was received in late 2022 and was already accounted for in the previously disclosed optical communications terminal backlog as of December 31, 2022.

08:44 EDT Marriott expects tightening in hotel financing to be short-term

08:44 EDT Marriott expects to return $3.6B-$4.1B to shareholders in 2023

08:41 EDT CLS Holdings, Oasis Cannabis Dispensary add The Real McCoy to shelves - CLS Holdings USA Inc., and Oasis Cannabis Dispensary are pleased to welcome The Real McCoy to our Dispensary shelves. The Real McCoy is a boutique cannabis company located in Nevada that prides themselves on producing the purest indoor grown cannabis.

08:39 EDT Moleculin Biotech completes first cohort in Phase 1b/2 trial of AML combination - Moleculin Biotech announced the successful completion of the first cohort in the Phase 1b portion of its Phase 1b/2 clinical trial using Annamycin in combination with Cytarabine for the treatment of AML. The median of prior therapies for these three subjects were 5 - 2 to 7 -. One of the subjects, who was 78 years of age at the time of study initiation with 2 prior multi-year therapies, was preliminarily recorded as a complete response at three weeks, or "CR", per the protocol. This was subsequently confirmed to be a durable CR after four weeks. The other two subjects were shown to have disease progression. Subjects have already been identified as potential candidates for the second cohort. The Phase 1b/2 MB-106 trial is an open label trial that builds on the safety and dosage data from the two concluded single agent Annamycin AML Phase 1 trials, MB-104 and MB-105, conducted in the U.S. and Europe, respectively.

08:38 EDT 3D Systems showcases portfolio enhancements at RAPID+TCT 2023 - 3D Systems announced it will showcase its additive manufacturing solutions at RAPID+TCT 2023 that are catalyzing innovation across industries including motorsports, semiconductor equipment, aerospace, and medical device manufacturing. The company's solutions comprising 3D printing technology, materials, software, and applications expertise are changing the landscape of design, engineering, and manufacturing. At RAPID+TCT 2023, 3D Systems is introducing portfolio enhancements - SLS Material Delivery Module, DMP Build Changeover Station, GRCop-42, CuCr1Zr - that will enable customers to expand the breadth of applications they can address with AM and enhance productivity.

08:37 EDT Workhorse Group to highlight W56 Step Van at ACT Expo - Workhorse Group announced its attendance at the upcoming Advanced Clean Transportation Expo, which is being held from May 1-4, 2023 in Anaheim, CA. As part of the Company's participation at ACT Expo, Workhorse plans to highlight the commercial readiness of its W56 step van which was formally unveiled in March at the NTEA Work Truck Show. Workhorse will be displaying a production intent vehicle and stripped chassis along with a dedicated W56 step van available for ride-and-drive opportunities during the event. Dealers are now taking pre-orders for W56 production slots in Q4 2023/Q1 2024 scheduling before production begins in Q3 2023.

08:36 EDT SurgePays approved to dual list on Upstream - SurgePays announced its approval to dual list its shares on Upstream, the revolutionary trading app for digital securities and NFTs powered by Horizon Fintex and MERJ Exchange Limited. Trading becomes available on Upstream May 8, 2023, at 10:00am ET under the ticker symbol "SURG''. The dual listing on Upstream is designed to provide SurgePays the opportunity to access a global, digital-first investor base outside the U.S. that can trade using USDC digital currency along with credit, debit, PayPal, and USD; unlocking liquidity and enhancing price discovery while globalizing the opportunity to invest in SurgePays..

08:36 EDT Marriott raises FY23 comparable systemwide RevPAR growth view to 10%-13% - Sees Q2 worldwide RevPAR growth 10%-12%. Sees FY23 RevPAR up 6%-9% for the U.S. and Canada, with Q2 up 5%-7%, and up 22%-25% for the international segment for FY23 and up 27%-29% for Q2. Sees FY23 gross rooms growth about 5.5% worldwide.

08:34 EDT Clearmind Medicine announces clinical supply agreement for upcoming trial - Clearmind Medicine announced an agreement with IMP Clinical Supply Services, IMP. IMP will be responsible for the global clinical supply chain of Clearmind's proprietary drug candidate CMND-100 from manufacture to the various clinical sites. IMP is known for its comprehensive, tailor-made clinical supply services that address all study requirements. The array of services to be performed are fully compliant with GMP, GCP, and GDP standards. Clinical drug supply is a critical factor for trial success so collaboration with best-in-class clinical drug supply vendor forestalls the possibility of it being a bottleneck to successful drug delivery. Moreover, it can also deliver enormous benefits, including better investigator and patient experiences as well as cost savings in clinical drug supply. The company's clinical trial is expected to commence in Q2 2023 in the United States and in Israel. The primary end point of the trial is to find the tolerable dose and characterize the safety and pharmacokinetics/ pharmacodynamics of single and repeated doses of CMND-100 in healthy subjects and those with Alcohol Use Disorder. The secondary end point is to preliminarily evaluate the efficacy of CMND-100 in reduction of drinking patterns and craving in individuals with moderate-to-severe AUD. Oral capsules will be administered once daily, for ten consecutive days. The patients will report their drinking patterns and craving for alcohol (and cigarettes) during the clinical trial period.

08:33 EDT Marriott: Transient booking window still short-term

08:33 EDT Apollo Global launches new product platform for global wealth markets - Apollo announced the launch of the Apollo Private Markets SICAV, a Luxembourg-based product platform designed to offer a holistic set of Apollo's alternative solutions to wealth investors in EMEA, Asia and Latin America, in formats tailored to individuals' specific needs. The platform received regulatory authorization from Luxembourg's Commission de Surveillance du Secteur Financier and launches with its first two investment strategies. The launch of the platform marks a significant milestone in the buildout of Apollo's Global Wealth business in regions outside of the United States. The new platform will initially offer two perpetual, semi-liquid products - one that provides a turn-key solution to broad private markets exposure and another focused on US private credit - and Apollo plans to add additional strategies in upcoming months. The SICAV structure will allow investors to access strategies in their local currency, with lower investment minimums than traditional alternative product offerings.

08:32 EDT MSA Safety raises quarterly dividend 2.2% to 47c from 46c per share - The quarterly dividend is payable June 10 to shareholders of record on May 16.

08:29 EDT Arcutis Biotherapeutics completes enrollment in ITNEGUMENT-PED Phase 3 trial - Arcutis Biotherapeutics announced the enrollment of the last subject in the INTEGUMENT-PED Pivotal Phase 3 trial evaluating roflumilast cream 0.05% for the treatment of mild to moderate AD in children ages 2 to 5. Roflumilast cream is a once-daily topical formulation of roflumilast, a highly potent and selective phosphodiesterase type 4 inhibitor, which the Company is evaluating in two doses for AD: 0.15% for adults and children 6 years of age and older, and 0.05% for children aged 2 to 5 years. Arcutis previously reported positive topline data in similarly designed Pivotal Phase 3 trials of roflumilast cream 0.15% in ages 6 and above. "Topical steroids are the first-line of treatment for AD in children, and there are few treatment options available for chronic use. It was critical for Arcutis that we developed and studied the effectiveness and safety of roflumilast cream in children as young as age 2 because of the tremendous burden AD can represent, including lack of sleep and persistent itch," said Patrick Burnett, MD, PhD, FAAD, Chief Medical Officer at Arcutis. "Roflumilast cream is a once-daily, steroid free treatment that was formulated to be a non-greasy, moisturizing cream that absorbs quickly. In addition, roflumilast cream does not include sensitizing excipients or irritants such as propylene glycol." The Company plans to report topline data for the INTEGUMENT-PED trial in the third quarter 2023.

08:26 EDT Verses Technologies demonstrates WAYFINDER intelligent routing agent - VERSES AI announced its participation as an Emerging Sponsor at Blue Yonder's ICON 2023 event, held in Las Vegas, NV from Tuesday, May 2nd through Friday, May 5th. This event brings together industry leaders, Blue Yonder customers, and innovative solutions at one event to explore the latest advancements in supply chain, logistics, and retail technology. At ICON 2023, VERSES will demonstrate the integration of their WAYFINDER Intelligent Routing Agent with Blue Yonder's Edge applications. This Agent is designed to optimize the routing of people, robots, drones, and other systems, dynamically adjusting their paths in real-time to ensure the most efficient routes relative to all other routes. The WAYFINDER Intelligent Routing Agent is the first in a series of Intelligent Agents that VERSES is developing in collaboration with Blue Yonder, a partnership that aims to revolutionize the supply chain and logistics industry by harnessing the power of artificial intelligence and advanced analytics.

08:24 EDT Immutep announces KOL event focused on eftilagimod alpha - Immutep announces a Key Opinion Leader event will be hosted by Ladenburg Thalmann & Co, Inc., on Tuesday, May 9, 2023, from 11:30 AM - 1:00 PM ET.

08:24 EDT Private Bancorp of America announces ANI settlement recovery - Private Bancorp of America and its wholly-owned subsidiary, CalPrivate Bank, announced that it had reached a settlement with the Receiver for ANI Investments and Gina Champion-Cain in which the Company will recover $7.6 million plus certain rights to future recoveries from a guarantor of the charged off loan. This recovery amount represents 80% of the original principal charge-off and is net of the participant bank's share.

08:21 EDT Eloxx Pharmaceuticals announces FDA clearance to begin SAD study off ZKN-013 - Eloxx Pharmaceuticals announced that the U.S. Food and Drug Administration has cleared the Company's Investigational New Drug application to initiate a single ascending dose clinical trial in healthy volunteers for ZKN-013 for the potential treatment of recessive Dystrophic Epidermolysis Bullosa with nonsense mutations. RDEB is a rare skin disease characterized by mutations in Collagen7 gene. Further SAD and multiple ascending dose testing is expected to be conducted following the completion of the planned dose cohorts in the SAD study and discussion with the FDA. The MAD testing could potentially include RDEB patients given the strong benefit/risk in patients cited by the FDA.

08:20 EDT TOI patient is first to receive new therapy for metastatic ovarian cancer - A new era of immunotherapy-based treatments for metastatic ovarian cancer is providing patients with an alternative to chemotherapy through Tempus Laboratories and The Oncology Institute, TOI. A Los Angeles patient of TOI became the first randomized patient worldwide be treated with this promising study drug in March. "We are thrilled to have been the first to administer this immunotherapy treatment for a patient who otherwise would have needed chemotherapy," said Dr. Paul La Porte, MD. "Our focus as a value-based oncology practice is on patient outcomes and satisfaction. Providing access to cutting-edge medicines through the Tempus-TIME Trial Program reduces a huge barrier for our patients." The TIME Trial Program is a just-in-time network of providers supporting rapid patient identification, site activation, and enrollment of select, cutting-edge clinical trials. TIME's ability to rapidly open, in an average of 10 days, allows hospitals in its network to easily tap into a marketplace of trials that they can quickly initiate when they have a patient that is ready to enroll.

08:18 EDT Ecolab expects 30c per share unfavorable impact in FY23 - The company said, "Ecolab continues to expect to deliver performance that improves despite a challenging macro environment characterized by high delivered product costs and easing demand. In addition, higher interest expense and currency translation are estimated to have a combined $0.30 per share unfavorable impact in 2023, or a 7% headwind to year-over-year earnings growth. The Company expects double-digit growth in organic operating income, driven by continued robust sales growth, easing delivered product cost inflation, and improved productivity. This strong performance is expected to more than overcome the challenging environment to deliver quarterly adjusted earnings per share growth that accelerates towards our low double-digit historical performance."

08:17 EDT Politan Capital nominates two candidates for Masimo board - Politan Capital Management, a 9% shareholder of Masimo Corporation, announced that it has nominated two candidates for election to the Masimo board of directors, Michelle Brennan and Quentin Koffey, Managing Partner and Chief Investment Officer of Politan. Koffey stated in part: "As a 9% owner of Masimo, Politan is fully aligned with the success of the company and its ability to generate long-term value. We believe independent oversight is needed on the Board in order to fix the lack of confidence in Masimo's governance that has led to a persistent valuation discount of over $4 billion. This is why Politan has nominated two ideally qualified director candidates for election at the 2023 Annual Meeting who are committed to representing the interests of all shareholders. Over the past eight months, we have attempted to engage constructively with Masimo's Board - but they have refused to even meet with us... By electing us, shareholders will be adding to the Board independent, objective directors with the right skills and experience to help the company maximize its potential for all its stakeholders."

08:15 EDT Uber says 'more confident than ever' in company's prospects - Says managing cost structure "dynamically." Expects head count "flat to down" for balance of the year. Says does not expect business to slow down materially, but will adjust if that occurs. Says looking "full stack" at AI. Says looking at AI for developer productivity. Expects AI to "return significantly" for the company going forward. Says innovating, adding lots of new options for riders. Comments taken from Q1 earnings conference call.

08:13 EDT Papa John's appoints Mark Shambura CMO, effective May 8 - Papa John's International announced the appointment of Mark Shambura to Chief Marketing Officer, effective May 8. Mr. Shambura is a brand marketing leader with deep expertise in growing multi-unit restaurant brands. He will oversee brand and advertising; media and field activation; menu strategy and product innovation; and the digital customer experience, including Papa Johns owned channels, loyalty program and aggregator partnerships.

08:11 EDT Agnico Eagle renews normal course issuer bid - Agnico Eagle Mines has received approval from the Toronto Stock Exchange of Agnico Eagle's notice of intention to renew its normal course issuer bid. Under the NCIB, Agnico Eagle may purchase for cancellation, on the open market at its discretion, during the period commencing on May 4, 2023 and ending on the earlier of May 3, 2024 and the completion of purchases under the NCIB, up to the lesser of: 24,718,919 common shares of Agnico Eagle, which is 5% of the issued and outstanding Common Shares; and that number of Common Shares that can be purchased by Agnico Eagle under the NCIB for an aggregate purchase price, excluding commissions, of not more than $500M, subject to the normal terms and limitations of such bids. Based on the closing share price of $56.59 on April 27, 2023, 8,835,483 Common Shares would be purchasable under the NCIB, representing approximately 1.79% of the issued and outstanding Common Shares as of April 27, 2023. As of April 27, 2023, Agnico Eagle had 494,378,388 issued and outstanding Common Shares. The NCIB will be funded using Agnico Eagle's existing cash resources, and any Common Shares repurchased by Agnico Eagle under the NCIB will be cancelled. Agnico Eagle has established an automatic share purchase plan in connection with its NCIB to facilitate the purchase of Common Shares during times when Agnico Eagle would ordinarily not be permitted to purchase Common Shares due to regulatory restrictions or self-imposed black-out periods.

08:09 EDT COMSovereign Holding signs new reseller agreement with CLAdirect - COMSovereign Holding has added CLAdirect, a wireless connectivity and solutions provider serving public and private network operators throughout Latin America, as a new business partner. Founded in 1997, CLAdirect currently serves an array of government and commercial customers throughout Latin America and the Caribbean with innovative solutions for business and advanced infrastructures leveraging cutting-edge technologies. COMSovereign and CLAdirect have worked together previously providing wireless connectivity solutions to several large network operators, especially in Mexico, where the company's DragonWave and Fastback Networks radios have received governmental certification.

08:04 EDT PPG appoints Christine Camsuzou as chief procurement officer - PPG announced that Christine Camsuzou, currently interim chief procurement officer, or CPO, has been appointed vice president, procurement and CPO, effective immediately. Reporting to Ram Vadlamannati, senior vice president, operations, Camsuzou will be responsible for leading PPG's global procurement team, processes and strategy.

08:02 EDT NeuroBo Pharmaceuticals: FDA clears IND for Phase 2a trial of DA-1241 - NeuroBo Pharmaceuticals announced that the U.S. FDA has cleared its Investigational New Drug application for DA-1241, a novel G-Protein-Coupled Receptor 119 agonist. The company plans to initiate a two-part, Phase 2a clinical trial of DA-1241, for the treatment of nonalcoholic steatohepatitis, in the third quarter of 2023.

07:58 EDT Nikola and Voltera partner for hydrogen station infrastructure - Nikola and Voltera, a provider of critical infrastructure necessary to support the full decarbonization of transportation, announced a definitive agreement to develop the hydrogen fueling infrastructure required to support Nikola's deployment of its zero-emissions vehicles. Through this strategic partnership agreement, Nikola and Voltera plan to develop up to 50 HYLA stations throughout North America over the next five years. This partnership underpins Nikola's prior announced plans to develop 60 stations by 2026. Through this partnership, Nikola and Voltera will create the largest North American open-network of commercial hydrogen refueling stations, providing fuel to vehicles from various manufacturers to accelerate the adoption of zero-emission vehicles. Voltera will site, build, own, and operate the strategically located, fit-for-purpose hydrogen refueling stations, and Nikola will supply the hydrogen fuel and provide technical expertise.

07:53 EDT Tenaya Therapeutics receives FDA fast track designation for TN-201 - Tenaya Therapeutics announced that the U.S. Food and Drug Administration has granted Fast Track designation for its gene therapy product candidate, TN-201, being developed for the treatment of Myosin Binding Protein C3-associated hypertrophic cardiomyopathy. TN-201 is Tenaya's potential first-in-class adeno-associated virus-based investigational gene therapy for the treatment of HCM caused by mutations in the MYBPC3 gene, the most common genetic cause of HCM. TN-201 is designed to deliver a fully functional MYBPC3 gene to restore normal levels of myosin-binding protein, which regulates the contraction and relaxation of the heart muscle. In preclinical studies of MYBPC3 knock-out models, TN-201 has been shown to halt disease progression and demonstrated significant and durable disease reversal and survival benefit after a single dose. In January 2023, Tenaya announced that the FDA cleared its Investigational New Drug application for TN-201. Tenaya is initiating the MyPeak-1 Phase 1b clinical trial to assess the safety, tolerability and clinical efficacy of a one-time intravenous infusion of TN-201. The multi-center, open-label study will enroll adults diagnosed with MYBPC3-associated nonobstructive HCM. Tenaya anticipates the first patient will be dosed in this clinical trial during the third quarter of 2023. Tenaya is also conducting two non-interventional studies to support the development of TN-201: a study evaluating seroprevalence to AAV9 antibodies among adults with MYBPC3-associated HCM, and MyClimb, a natural history study of pediatric patients with MYBPC3-associated HCM.

07:48 EDT Bombardier announces environmental product declarations for Global 5500, 6500 - Bombardier announced that it has completed a thorough analysis of the Global 5500 and Global 6500 in order to publish Environmental Product Declarations for two of its large aircraft. They join the Global 7500 aircraft and the Challenger 3500 aircraft as business aviation's only EPD-designated jets. "The publication of the Global 5500 and Global 6500 aircraft EPDs are the results of years of scientific effort," said Michel Ouellette, Executive Vice President, Engineering and Product Development, Bombardier. "These declarations are more than brochures: they are tools for the aviation industry to drive sustainable innovations across its activities spectrum. They are also the outcome of the thoroughness, mindfulness and ingenuity of a uniquely skilled internal team of experts. As a company, we are immeasurably proud that the reputation of our products and exciting opportunities attract the best minds in the world."

07:45 EDT ARway.ai announces Magic Leap AR Glasses integration - ARway has begun integration development and expects to complete the integration in the next 60-days for one of the most widely used AR Glasses; Magic Leap Glasses. Magic Leap Glasses are an immersive enterprise AR device that combine the virtual and real worlds to create a unique and immersive user experience. These glasses use advanced technologies like eye-tracking, spatial sound, and 6DoF to enable users to interact with digital content in the real world. With the integration, the expansion of ARway's product offerings provide customers with greater device compatibility beyond mobile phones, which will increase use cases and application of technology. As Magic Leap hardware is improving at a rapid pace, they are now able to support large-scale experiences with improved environmental understanding which is a great fit for the capabilities of the ARway platform and opens up the platform for the existing and growing installed base of companies in the magic leap ecosystem.

07:41 EDT Laser Photonics sells third system to Galiardi Laser Clean - Laser Photonics announced the sale of a third system to Galiardi Laser Clean based in Missouri.

07:40 EDT Eightco Holdings begins non-deal roadshow - Eightco Holdings announced the kick-off of its non-deal roadshow for institutional investors in the United States. As previously disseminated on April 10th, 2023, the event will be hosted by a large institutional investment firm and provide attendees with a comprehensive understanding of the company's business model as it is expected to apply to existing and future shareholders. The NDRs will begin today, May 2, 2023. Over the course of the roadshow, Eightco Holdings Inc. will focus on its wholly-owned subsidiary, Forever 8, including its underlying disruptive suite of inventory management solutions. Eightco Holdings Inc. will also highlight and review its roadmap towards synergistic partnerships and planned path to profitability.

07:34 EDT Harmony Biosciences announces upcoming, data - Continued strong momentum in the Phase 3 registrational trial in adult patients with IH, with topline data anticipated in the fourth quarter of 2023. End-of-Phase 2 meeting with the U.S. Food and Drug Administration scheduled for late second quarter of 2023 to discuss the Prader-Willi Syndrome Phase 2 proof-of-concept study results and a proposed Phase 3 trial in patients with PWS. Enrollment continues in our Myotonic Dystrophy study. Anticipates topline data from this Phase 2 proof-of-concept trial in the fourth quarter of 2023.

07:29 EDT Osisko Mining, Gold Field announce 50/50 joint venture of Windfall Gold Project - Osisko Mining (OBNNF) announces it has concluded a 50/50 joint venture agreement with a subsidiary of Gold Fields (GFI) for the joint ownership and development of Osisko's Windfall gold project, located in the Abitibi greenstone belt, Urban Township, Eeyou Istchee James Bay, Quebec. Transaction Highlights: Gold Fields initial cash payment to Osisko of C$300M on signing. Gold Fields additional cash payment to Osisko of C$300 million on issuance of the applicable permits authorizing the construction, operation and mining of the Windfall Project. Gold Fields to sole fund expenditures for regional exploration up to a maximum of C$75 million, after which regional exploration programs would be proportionately funded by each of Osisko and Gold Fields. In addition to the initial cash payment and the Deferred cash payment, Gold Fields to make two additional separate C$17 million cash payments to Osisko. These represent reimbursement of items already incurred by Osisko as part of pre-construction spend. Gold Fields and Osisko share all pre-construction costs and construction costs on a 50/50 basis going forward. Governance arrangements with equal representation in the Partnership from Osisko and Gold Fields, to leverage each party's skillsets. Osisko's Chairman and Chief Executive Officer, John Burzynski, stated: "We are very pleased to partner with Gold Fields on the Windfall project and our exploration property portfolio. Today is the start of what we believe will prove to be a long and fruitful partnership with Gold Fields at Windfall, and in what we both believe is a significant emerging gold district in Quebec. This partnership further strengthens our strong balance sheet, allows us to significantly de-risk Windfall and brings us a very important step closer to realizing our objective of becoming a leading Canadian gold producer. With the proceeds from this Transaction, Osisko is fully-funded for our share of development capital to bring Windfall into production. Osisko shareholders retain considerable upside in the project while also benefiting from the mine building, operating and technical expertise of Gold Fields. Assuming the project is ultimately permitted and approved by the partners consistent with the Windfall Feasibility Study, Gold Fields' acquisition cost, exploration commitment, and contribution to pre-construction and project capital would ultimately represent an investment of C$1.2 billion to acquire its interest, bring Windfall into production and further unlock the regional exploration upside. This Transaction is highly compelling on many fronts and represents the best path forward to maximize value for all stakeholders."

07:28 EDT WisdomTree issued a letter to its stockholders for nominee support - WisdomTree issued a letter to its stockholders regarding WisdomTree's 2023 Annual Meeting of Stockholders , which is scheduled to be held on June 16. At the 2023 Annual Meeting, WisdomTree stockholders will have the opportunity to protect their investment in the Company by choosing to elect the following six highly qualified nominees to the Company's Board: Lynn S. Blake, Daniela Mielke, Shamla Naidoo, Win Neuger, Frank Salerno and Jonathan Steinberg. Each of these nominees possesses significant and extensive experience relevant to WisdomTree's business strategy, including global financial, accounting, compliance, technology and digital expertise, and many years in senior leadership positions in the investment management and financial services industries. WisdomTree urges its stockholders to vote for all six of WisdomTree's nominees on the WHITE proxy card TODAY. A dissident stockholder, ETFS Capital Limited is seeking to elect three representatives to the WisdomTree Board, including the chairman of ETFS Capital, Graham Tuckwell, who has been pursuing a multi-year crusade against WisdomTree driven purely by his personal agenda and ego, rather than by any consideration of what is best for the Company and its stockholders.

07:27 EDT SciSparc completes treatment of last patient enrolled in Phase IIa trial - SciSparc announced that the last patient enrolled in the Company's Phase IIa trial of SCI-110 in patients with Alzheimer's Disease and agitation, completed its treatment. The Company is expecting to receive the final trial results in the upcoming weeks. On November 7, 2022, the Company announced positive interim results from the open label trial, which includes 20 patients diagnosed with AD and agitation, to evaluate the safety, tolerability and efficacy trends of twice daily oral administration of SCI-110. The interim results summarize the data from the first eight patients who completed the trial as per protocol. At the interim analysis, the trial met its primary endpoints of safety, including non-treatment related adverse events and drop out patients from the trial; specifically, SCI-110 did not cause delirium, oversedation, hypotension or falls even in the highest dose tested. In addition, the interim analysis showed that the trial also met its secondary endpoint of change from baseline to end of treatment in agitation measured by the Cohen Mansfield Agitation Inventory; out of the eight patients, six showed amelioration in agitation with no need to use rescue medication to control agitation. CMAI is a standard measure for measuring agitation in people with dementia. Additionally, the interim analysis showed in the exploratory endpoints that appetite was increased in six out of the eight patients, as measured by the Edinburgh Feeding Evaluation in Dementia Scale. No effect was observed on cognitive measurements and sleep quality, as measured by the Mini Mental State Exam, and by the Alzheimer's Disease Assessment Scale-cognitive subscale and the Pittsburgh Sleep Quality Index. In general, the trial medication was well tolerated with no negative response to the treatment observed during the duration of the trial. The trial, titled "Phase II-a Open Label Trial to Evaluate the Safety, Tolerability and Efficacy Trend of SCI-110 in Patients with Alzheimer's Disease and Agitation" is being conducted at The Israeli Medical Center for Alzheimer's under the leadership of Dr. Alexander Kaplan, MD, principal investigator and board-certified geriatrician.

07:25 EDT Immatics reports interim clinical data from ongoing Phase 1b Cohort A - Immatics announced an interim clinical data update for 11 patients with recurrent and/or refractory solid cancers treated with ACTengine IMA203 TCR-T monotherapy in the ongoing Phase 1b dose expansion Cohort A. IMA203 TCR-T cells are directed against an HLA-A*02-presented peptide derived from PRAME, a broadly expressed solid cancer target with clinical proof-of-concept for IMA203 demonstrated by Immatics in 2022. Overall, IMA203 showed a high rate of deep and durable objective responses, with a confirmed objective response rate of 67%, across multiple tumor types, including two confirmed partial responses, cPR, ongoing at more than 9 months after treatment and three additional partial responses ongoing at data cut-off. IMA203 monotherapy continues to be well tolerated in heavily pre-treated patients at doses of up to approximately 9 billion CD8+ TCR-T cells. No high-grade cytokine release syndrome, CRS, and no immune effector cell associated neurotoxicity syndrome, ICANS, were observed in Cohort A at data cut-off. Safety data for IMA203 TCR-T monotherapy in Phase 1b Cohort A: Treatment with IMA203 monotherapy continues to show manageable tolerability at doses as high as ~9x109 TCR-T cells. At data cut-off on April 4, 2023, 11 PRAME-positive patients were infused with IMA203 TCR-T cells at dose level 4 or DL5 with a mean total infused dose of 3.67x109 TCR-T cells. Based on data review of 6 patients in the exploratory highest DL5, this DL was cleared by the DSMB for safety, and the updated provisional recommended Phase 2 dose now includes DL4 and DL5. The final RP2D will be defined prior to starting Phase 2. Most frequent treatment-emergent adverse events were as expected for cell therapies. All 11 patients experienced expected cytopenia associated with lymphodepletion. 10 patients had a low to moderate cytokine release syndrome, of which 5 patients had Grade 1, and 5 patients had Grade 2 CRS. No high-grade CRS and no immune effector cell associated neurotoxicity syndrome were observed in any of these 11 patients. No dose-dependent increase of CRS was observed across Phase 1a and Phase 1b Cohort A. At data cut-off on April 4, 2023, 11 patients were infused with IMA203 TCR-T cells and evaluable for at least one tumor response assessment post treatment. Objective responses were observed in last-line solid cancer patients including cutaneous melanoma, ovarian cancer, uveal melanoma, head and neck cancer, synovial sarcoma. Initial objective response rate of 64% was observed at ~week 6. Confirmed ORR of 67% was observed at ~month 3; initial responses at week 6 were confirmed for all 6 responders with available subsequent 3-month scan. Median duration of response was not reached at a median follow-up3 of 8.5 months. Immatics believes, the results presented today further validate PRAME as one of the most promising solid tumor targets for TCR-based therapies. Immatics' IMA203 development strategy is based on two pillars aimed initially at a fast-to-market approach and, later at a broad development. As a second step, Immatics plans to also expand development to other cancer types, such as uterine cancer, lung cancer, breast cancer, head and neck cancer and other tumor types having a broad patient reach. An update on all three IMA203 Phase 1b Cohorts and clinical development path for PRAME TCR-T monotherapy towards registration-directed trials and potential commercialization is planned for 4Q 2023.

07:20 EDT Compass, MAPS PBC announce AMA has approved code for psychedelic therapies - COMPASS Pathways and MAPS Public Benefit Corporation, MAPS PBC, announced that the American Medical Association, AMA, has approved a Current Procedural Terminology, CPT, III code for psychedelic therapies. The full details of the code are expected to be released by the AMA in July 2023 and the code will go into effect when it is published on January 1, 2024. Once effective, the CPT code will provide physicians and other qualified healthcare professionals a means to code and seek reimbursement for delivering psychedelic therapies. The application for the new CPT III code was the result of a collaboration between MAPS PBC and COMPASS Pathways to facilitate reimbursement and ultimately access to psychedelic therapies in the US, if approved by the US Food Drug Administration, FDA. Both companies are working to develop and, subject to FDA approval, commercialize psychedelics as part of a new treatment paradigm for individuals with mental health conditions. COMPASS Pathways is conducting a phase 3 program of investigational COMP360 psilocybin therapy in treatment-resistant depression, TRD, having already published positive results in the New England Journal of Medicine from its phase 2b study of COMP360 in TRD, in the largest study of its kind. MAPS PBC has completed two phase 3 clinical trials evaluating MDMA-assisted therapy as a potential treatment for post-traumatic stress disorder, both of which met their pre-specified primary and secondary endpoints. This new code may provide a mechanism by which these new treatments being developed by COMPASS and MAPS PBC could be reimbursed if they are approved by the FDA. "This is a major step forward to enabling broad and equitable access to psychedelic therapies," said Kabir Nath, CEO, COMPASS Pathways. "This collaboration with MAPS PBC to develop a new CPT code aims to ensure that psychedelic therapies, if approved, could be integrated into healthcare systems, reimbursed by payers, and made available to the people who need them."

07:20 EDT Pfizer CEO sees 'robust operational growth through 2025 and beyond' - Dr. Albert Bourla, Chairman and CEO, stated: "This is an exciting time for Pfizer as we are already executing on and rigorously planning for an unprecedented number of anticipated new product and indication launches, most of which are expected to occur in the second half of 2023. We have made excellent progress toward this goal already this year with the U.S. approvals for Zavzpret, Cibinqo for adolescents and Prevnar 20 in pediatric patients, and regulatory filing acceptances for a Braftovi + Mektovi sNDA, sNDA for the Talzenna and Xtandi combination, elranatamab BLA and our RSV maternal vaccine candidate - which, if approved, would be the first vaccine for administration to pregnant individuals to help protect against the complications of RSV disease in infants from birth up to six months of age. During the first quarter, we announced plans to advance the battle against cancer with a definitive agreement to acquire Seagen, a global biotechnology company that discovers, develops and commercializes transformative oncology medicines. By combining Seagen's category-leading antibody-drug conjugate technology with Pfizer's scale, expertise and capabilities, we believe we can accelerate breakthroughs in cancer medicines and introduce new solutions to patients around the world. Oncology remains a core therapeutic area for Pfizer, and we believe the proposed acquisition will enhance our position in this important space. We believe the strength of our in-line products and expected near-term launches and revenue contribution from business development activities, including the proposed acquisition of Seagen, will position Pfizer to deliver robust operational growth through 2025 and beyond."

07:19 EDT Solaris Resources confirms discovery of second porphyry center - Solaris Resources confirms the discovery of a second and more intensely mineralized porphyry center 350m south of the original discovery at Warintza East. The new discovery holds potential for notably improved grades in further growth at the Warintza Project in southeastern Ecuador. Warintza East was discovered in July 2021, with eight holes included in the Warintza Central Mineral Resource Estimate in April 2022 and subsequent drilling significantly expanding the dimensions of the deposit - the latest drilling in SLSE-28 has confirmed the discovery of a second and more intensely mineralized porphyry center 350m south of the original discovery SLSE-28 was drilled vertically to the limit of the KD-200 rig at 309m with strong mineralization from 19m to the end of the hole characterized by chalcopyrite-pyrite-molybdenite in stockwork veins and disseminations, similar to the high grade portions of the Warintza Central deposit; Full assay results from SLSE-28 are expected within four to six weeks while follow-up hole; SLSE-29 is being drilled southeast from a recently constructed platform testing the extension of this new porphyry center up to 200m to the east in this area; This new porphyry center is located on the southern margin of Warintza East drilling and correlates with mineralization encountered in the high grade portion of prior hole SLSE-16 in this area ;MRE drilling program continues: the 2022 MRE is based on drilling to the end of 2021, with ongoing drilling aimed at expanding the 'Indicative Starter Pit' and overall mineral resources, notably from the Warintza East deposit

07:17 EDT Aclarion appoints Nicholas Theodore as Principal Investigator - Aclarion announced that Nicholas Theodore, MD, Director of Neurosurgical Spine Center at Johns Hopkins University, will serve as the Principal Investigator in a post-market, multi-site trial, that will further evaluate the role of Nociscan in the diagnosis and surgical treatment of patients suffering from chronic low back pain. Building on the success of the recently published Gornet 2YR clinical outcomes, CLARITY will expand the protocol of the Gornet study to up to 14 sites and target enrollment of approximately 300 patients. CLARITY represents a new post-market clinical trial for Aclarion. "Aclarion is excited to add this important evidence to our portfolio and honored that Dr. Theodore from Johns Hopkins has enthusiastically accepted the PI role," says Brent Ness, CEO of Aclarion. "CLARITY will add to the compelling two-year outcomes of the Gornet trial and the cost-effectiveness health economics study."As previously announced, Aclarion has been used in two National Institutes of Health trials in the US focused on improved understanding of low back pain and the effect of non-surgical treatment options.

07:16 EDT Lithium Ionic initiates 20,000m drill program at Salinas Project - Lithium Ionic reports the initiation of a planned 20,000 metre drilling program on claims within its newly acquired Salinas Project, located in the northern region of Minas Gerais State, Brazil, in the lithium-rich Aracuai Pegmatite District. The Company has engaged Brazil's largest drilling company, Geosol, to complete the program, which aims to define and expand multiple lithium-bearing spodumene-rich pegmatite veins identified with surface sampling and drilling in 2022. Two drill rigs are currently operating on the property, with an additional two expected to be mobilized in the coming weeks. Highlights: Initiation of a 20,000-metre diamond drilling program; Two drills operating, with an additional two being mobilized in the coming weeks; The drill program is designed to test, define, and expand multiple lithium-bearing spodumene-rich pegmatites identified in 2022, which returned drill intercept highlights of: 1.53% Li2O over 11.36m from 43.8m; 1.22% Li2O over 13.76m from 36.6m; 1.71% Li2O over 9.82m from 97.7m; 1.19% Li2O over 13.35m from 239.7m. Blake Hylands, P.Geo., Chief Executive Officer of Lithium Ionic, commented, "While we are focused on delivering our maiden mineral resource estimates at Bandeira and Galvani in Q2 of this year, we are very excited to kick off drilling at this promising target. 2022 drilling showed strong grade and widths from well-formed, coarse-grained spodumene in pegmatites, extending directly northeast of Latin Resources' ~13Mt @ 1.2% Li2O Colina deposit. Our current drill pads are only 500 metres from Colina and the potential to expand much further to the east is evidenced by surface pegmatite showings and nearby historical artisanal workings that have been active for decades. We believe this new target will be an important addition to our growing story and likely contribute to a significant project update later this year."

07:14 EDT Sunoco LP raises 2023 adjusted EBITDA view to $865M-$915M from $850M-$900M - Raises 2023 maintenance capital expenditures view to $65M from $60M.

07:14 EDT Eneti announces contract award for Seajacks - Eneti announced that Seajacks UK Limited, a wholly-owned subsidiary of the company, has signed a contract in NW Europe, starting in the fourth quarter of 2023, for between 90 and 145 days of employment for one of its NG2500-class vessels that will generate between approximately $5.9M-$9.5M of revenue during the fourth quarter 2023 and the first quarter of 2024.

07:12 EDT ADMA Biologics announces amendment to credit agreement - ADMA Biologics announced the Company has amended the terms of its existing senior credit facility with Hayfin Capital Management, which matures in March 2027. The amended credit agreement provides for multiple favorable changes. First, there will be a reduction of 1% in the nominal interest expense on ADMA's current note. This will result in a lowered borrowing rate of SOFR + 8.50%. Included in this base rate, and consistent with the existing terms of the Hayfin facility, the Company may elect to pay up to 2.50% of the interest in kind, with the remaining portion of the interest payable in cash. Secondly, within the first 24 months after the amendment closing date, among other provisions, there will be a newly structured 50% waiver of the prepayment fee in connection with an acquisition of the Company or other strategic transactions. Taken together, we believe these changes will reduce ADMA's cost of capital and provide for added financial flexibility over the near term and on an ongoing basis. The debt financing terms disclosed in this press release are not all inclusive and, as such, the statements in this press release are qualified in their entirety by reference to the description of the debt financing further detailed in a Securities and Exchange Commission filing on Form 8-K which will be filed concurrently with this press release.

07:08 EDT LGI Homes sees 2023 home closings 6,300-7,100 - Subject to the caveats in the Forward-Looking Statements section of this press release, the Company is providing the following updates to its guidance for the full year 2023. The Company now expects: Home closings between 6,300 and 7,100; Active selling communities at the end of 2023 between 115 and 125; Average sales price per home closed between $345,000 and $360,000; Gross margin as a percentage of home sales revenues between 21.0% and 23.0%; Adjusted gross margin as a percentage of home sales revenues between 22.5% and 24.5% with capitalized interest accounting for substantially all the difference between gross margin and adjusted gross margin; SG&A as a percentage of home sales revenues between 12.5% and 13.5%; Effective tax rate between 23.5% and 24.5%.

07:04 EDT USA Compression still sees 2023 net income $75M-$95M

06:55 EDT Marathon Petroleum increases share repurchase authorization by $5B - Additionally, the board of directors has approved an incremental $5B share repurchase authorization. With the addition of this new authorization, the company has a total of $9B available under its share repurchase authorization. The authorization has no expiration date. MPC may utilize various methods to effect the repurchases, which could include open market repurchases, negotiated block transactions, accelerated share repurchases, tender offers or open market solicitations for shares, some of which may be effected through Rule 10b5-1 plans. The timing of repurchases will depend upon several factors, including market and business conditions, and repurchases may be discontinued at any time.

06:23 EDT Syneos Health appoints Michael Bonello as CFO - Syneos Health appointed Michael Bonello as CFO, effective July 1. Stanford Rudnick will continue to serve as Interim CFO until that time. Bonello most recently served as Chief Financial Officer of Clario, a clinical trial data collection company, since 2021. From 2008 to 2021, Bonello held roles of increasing responsibility at Nasdaq-listed PRA Health Sciences, including Executive Vice President and Chief Financial Officer from 2018 through the company's sale to ICON plc, and previously as Senior Vice President, Accounting and Corporate Controller from 2008 to 2018. Earlier in his career, he held financial leadership roles at Cree, Inc. and Genworth Financial, and was a senior manager in the audit practice at PricewaterhouseCoopers LLP.

06:17 EDT HSBC 'confident' in achieving RoTE target of at least 12% for 2023 onwards - HSBC said: "We remain confident of achieving our return on average tangible equity target of at least 12% for 2023 onwards, which is not dependent on the impact of material acquisitions and disposals. Our 1Q23 annualized RoTE of 27.4% included the annualized impact of our provisional gain on the acquisition of SVB UK and the reversal of an impairment on the planned sale of our retail banking operations in France. After excluding these transactions, annualized RoTE was 19.3%. The annualized RoTE in the first quarter is likely to be higher than in other quarters due to revenue seasonality, and as we do not expect certain favorable tax impacts to recur in subsequent quarters. Based on the current market consensus for global central bank rates, our net interest income expectations are unchanged from our fullyear guidance. After including an approximately $2bn reduction due to the implementation of IFRS 17 'Insurance Contracts', we expect to achieve net interest income of at least $34bn in 2023. We continue to use a range of 30bps to 40bps of average loans for planning our ECL charges over the medium to long term. While the ECL charge in 1Q23 was relatively benign, given current macroeconomic uncertainty we maintain the guidance provided at our full-year 2022 results of around 40bps of average gross loans in 2023. We continue to monitor risks related to our exposures in mainland China's commercial real estate sector. Our current intention is to manage the CET1 ratio within our medium-term target range of 14% to 14.5%, with a dividend payout ratio of 50% for 2023 and 2024, excluding material notable items."

06:12 EDT BP sees FY23 CapEx at lower end of range - Based on bp's current forecasts, at around $60 per barrel Brent and subject to the board's discretion each quarter, bp expects to be able to deliver share buybacks of around $4.0 billion per annum, at the lower end of its $14-18 billion capital expenditure range, and have capacity for an annual increase in the dividend per ordinary share of around 4%. bp remains committed to using 60% of 2023 surplus cash flow for share buybacks, subject to maintaining a strong investment grade credit rating.

06:07 EDT Northwest Natural Gas begins RNG production at second Tyson Foods facility - NW Natural Holding subsidiary NW Natural and BioCarbN, a developer and operator of environmental infrastructure projects, began production at a second renewable natural gas - RNG - facility, as part of a project partnership with Tyson Foods. The facility is located in Dakota City, Nebraska, with NW Natural investing approximately $12M to convert methane captured from the facility's operations into RNG to heat homes and businesses. The first project began at Tyson's Lexington, Nebraska operations in January 2022. At full capacity, the two projects combined are expected to produce about 240,000 MMBtu of RNG each year.

05:47 EDT Writers Guild of America goes on strike after studio talks fail - The Writers Guild of America said that after not reaching an agreement with Hollywood studios and streamer, its members will be on strike after the contract expired at midnight. "Your WGA Negotiating Committee spent the last six weeks negotiating with Netflix (NFLX), Amazon (AMZN), Apple (AAPL), Disney (DIS), Discovery-Warner (WBA), NBC Universal, Paramount (PARA) and Sony (SNY) under the umbrella of the Alliance of Motion Picture and Television Producers," the union told its members. It added, "Though we negotiated intent on making a fair deal-and though your strike vote gave us the leverage to make some gains - the studios' responses to our proposals have been wholly insufficient, given the existential crisis writers are facing." On April 10, BMO Capital lowered its 2023 funds from operations estimate for Hudson Pacific Properties (HPP) by 5%, primarily due to the likely Writers Guild of America strike in May. A strike would significantly impact Hudson Pacific's studio business, and the immediate impact, coupled with office and debt market uncertainty, would almost certainly lead Hudson Pacific to cut its dividend, said the firm. Reference Link

05:17 EDT Bally's enters exclusive sports betting pacts with Kambi, White Hat Gaming - Bally's announced that, after conducting a thorough evaluation, it has entered into exclusive, multi-year agreements with Kambi Group and White Hat Gaming to serve as Bally's B2B online sports betting, or OSB, and platform providers. Combining these services with Bally's core strengths, including its footprint, which will consist of 17 casinos across 11 states once ongoing projects are completed, a proprietary player database, an integrated Bally Rewards program, and a cross-functional marketing operation, will support the relaunch of Bally Bet, Bally's online sports betting platform, which the company expects to occur across seven states and at four retail gaming locations by the end of 2023. They will also enable Bally's to expand its OSB presence globally over time. Through these partnerships, Bally's will leverage Kambi's and White Hat's proven technology integration, extensive licensing across regulated jurisdictions, end-to-end solutions, and track record of executing quick launches to support the expansion and enhancement of its online and retail sportsbooks. In addition, the fixed cost structure previously associated with powering Bally's B2C sports betting platforms will shift to a variable cost structure that will generate significant cost savings and reduce risk. Under the terms of the Kambi partnership, Bally's will integrate Kambi's mature suite of omnichannel products, trading capabilities, content solutions, and model driven approach to liability management to deliver unrivaled online and retail sports betting entertainment, and iGaming offerings, to Bally's global customer base. Additionally, Bally's maintains the option, pending the satisfaction of certain material performance metrics, to acquire a license to a limited part of Kambi's online and retail technology source code. Should Bally's exercise the option and pay an agreed sum, the two parties would enter into a separate long-term outsourcing agreement in relation to Kambi's range of modularized services.